Active, not recruitingPhase 2NCT05504252
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Studying Mucinous adenocarcinoma of the appendix
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Akershus
- Principal Investigator
- Christian Kersten, MD, PhDUniversity Hospital, Akershus
- Intervention
- Nivolumab(drug)
- Enrollment
- 80 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (3)
- Akershus University Hospital, Lørenskog, Akershus, Norway
- Oslo University Hospital, Oslo, Akershus, Norway
- St Olavs Hospital, Trondheim, Trøndelag, Norway
Collaborators
Oslo University Hospital · St. Olavs Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05504252 on ClinicalTrials.govOther trials for Mucinous adenocarcinoma of the appendix
Additional recruiting or active studies for the same condition.
See all trials for Mucinous adenocarcinoma of the appendix →